| abstract |
The present invention relates to a composition, which comprises, as active ingredients, (1) an ASCT2 inhibitor, (2) a biguanide-based compound or a pharmaceutically acceptable salt thereof, and (3) 2-deoxy-D-glucose; which further comprises, in addition to the aforementioned ingredients, (4) inositol hexaphosphate or a pharmaceutically acceptable salt, inositol, or a mixture thereof, as an active ingredient; or which further comprises, in addition to the aforementioned ingredients, (5) an immune checkpoint inhibitor as an active ingredient. The composition according to the present invention exhibits a synergistic anticancer effect by appropriately combining specific drugs having a problem of needing to be used in excess, and thus can kill cancer cells and effectively treat cancer with even a small amount. Furthermore, the composition of the present invention can kill only cancer cells without side effects by showing a cancer-specific toxic effect while not showing toxicity in normal cells, and thus can be advantageously used as an anticancer drug or as a composition for prevention or alleviation of cancer. |